Difference between revisions of "Peginterferon alfa-2a (Pegasys)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or" to "or") |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood. Pegylation results in a much longer half-life compared to [[Interferon alfa-2a (Roferon-A)]].<ref name="insert">[ | + | Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood. Pegylation results in a much longer half-life compared to [[Interferon alfa-2a (Roferon-A)]].<ref name="insert">[https://www.gene.com/gene/products/information/pegasys/pdf/pi.pdf Peginterferon alfa-2a (Pegasys) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/peginterferonalfa-2a.pdf Peginterferon alfa-2a (Pegasys) package insert (locally hosted backup)]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 12: | Line 12: | ||
*[[Polycythemia vera]] | *[[Polycythemia vera]] | ||
| + | ==Diseases for which it was used== | ||
| + | *[[Osteosarcoma - historical|Osteosarcoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-patient-drug-information Peginterferon alfa-2a (Pegasys) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-patient-drug-information Peginterferon alfa-2a (Pegasys) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-patient-drug-information Peginterferon alfa-2a (Pegasys) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-patient-drug-information Peginterferon alfa-2a (Pegasys) patient drug information (UpToDate)]</ref> | ||
| Line 36: | Line 38: | ||
[[Category:Polycythemia vera medications]] | [[Category:Polycythemia vera medications]] | ||
| + | [[Category:Osteosarcoma medications (historic)]] | ||
[[Category:FDA approved in 2002]] | [[Category:FDA approved in 2002]] | ||
[[Category:EMA approved in 2001]] | [[Category:EMA approved in 2001]] | ||
Latest revision as of 00:14, 6 July 2024
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood. Pegylation results in a much longer half-life compared to Interferon alfa-2a (Roferon-A).[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.[1]
Diseases for which it is used
Diseases for which it was used
Patient drug information
History of changes in FDA indication
- 2002-10-16: Initial approval for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not been previously treated with interferon alfa.
History of changes in EMA indication
- 2001-07-05: EURD
Also known as
- Brand name: Pegasys